vs
Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and Urban Edge Properties (UE). Click either name above to swap in a different company.
Urban Edge Properties is the larger business by last-quarter revenue ($132.6M vs $123.8M, roughly 1.1× NATURES SUNSHINE PRODUCTS INC). Urban Edge Properties runs the higher net margin — 17.1% vs 3.3%, a 13.8% gap on every dollar of revenue. On growth, Urban Edge Properties posted the faster year-over-year revenue change (12.2% vs 4.7%). Over the past eight quarters, Urban Edge Properties's revenue compounded faster (11.6% CAGR vs 5.6%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
Urban Edge Properties is a publicly traded real estate investment trust (REIT) that owns, operates, and develops high-quality retail and mixed-use properties, primarily located in densely populated urban and suburban markets across the United States. Its portfolio covers grocery-anchored shopping centers, lifestyle outlets, and community-focused commercial assets.
NATR vs UE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $132.6M |
| Net Profit | $4.1M | $22.6M |
| Gross Margin | 72.5% | — |
| Operating Margin | 4.3% | — |
| Net Margin | 3.3% | 17.1% |
| Revenue YoY | 4.7% | 12.2% |
| Net Profit YoY | 1379.4% | -6.7% |
| EPS (diluted) | $0.23 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $132.6M | ||
| Q4 25 | $123.8M | $119.6M | ||
| Q3 25 | $128.3M | $120.1M | ||
| Q2 25 | $114.8M | $114.1M | ||
| Q1 25 | $113.2M | $118.2M | ||
| Q4 24 | $118.2M | $116.4M | ||
| Q3 24 | $114.6M | $112.4M | ||
| Q2 24 | $110.6M | $106.5M |
| Q1 26 | — | $22.6M | ||
| Q4 25 | $4.1M | $12.4M | ||
| Q3 25 | $5.3M | $14.9M | ||
| Q2 25 | $5.3M | $58.0M | ||
| Q1 25 | $4.7M | $8.2M | ||
| Q4 24 | $-321.0K | $30.1M | ||
| Q3 24 | $4.3M | $9.1M | ||
| Q2 24 | $1.3M | $30.8M |
| Q1 26 | — | — | ||
| Q4 25 | 72.5% | — | ||
| Q3 25 | 73.3% | — | ||
| Q2 25 | 71.7% | — | ||
| Q1 25 | 72.1% | — | ||
| Q4 24 | 72.0% | — | ||
| Q3 24 | 71.3% | — | ||
| Q2 24 | 71.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.3% | 11.3% | ||
| Q3 25 | 7.0% | 13.4% | ||
| Q2 25 | 3.7% | 53.9% | ||
| Q1 25 | 5.4% | 7.6% | ||
| Q4 24 | 3.8% | 27.6% | ||
| Q3 24 | 4.6% | 8.9% | ||
| Q2 24 | 5.1% | 30.6% |
| Q1 26 | — | 17.1% | ||
| Q4 25 | 3.3% | 10.4% | ||
| Q3 25 | 4.2% | 12.4% | ||
| Q2 25 | 4.6% | 50.8% | ||
| Q1 25 | 4.2% | 6.9% | ||
| Q4 24 | -0.3% | 25.9% | ||
| Q3 24 | 3.8% | 8.1% | ||
| Q2 24 | 1.2% | 28.9% |
| Q1 26 | — | $0.18 | ||
| Q4 25 | $0.23 | $0.09 | ||
| Q3 25 | $0.30 | $0.12 | ||
| Q2 25 | $0.28 | $0.46 | ||
| Q1 25 | $0.25 | $0.07 | ||
| Q4 24 | $-0.02 | $0.25 | ||
| Q3 24 | $0.23 | $0.07 | ||
| Q2 24 | $0.07 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.9M | $50.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $161.6M | $1.4B |
| Total Assets | $261.1M | $3.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $50.0M | ||
| Q4 25 | $93.9M | $48.9M | ||
| Q3 25 | $95.6M | $77.8M | ||
| Q2 25 | $81.3M | $53.0M | ||
| Q1 25 | $86.5M | $48.0M | ||
| Q4 24 | $84.7M | $41.4M | ||
| Q3 24 | $78.7M | $67.9M | ||
| Q2 24 | $68.7M | $78.6M |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $161.6M | $1.4B | ||
| Q3 25 | $166.7M | $1.4B | ||
| Q2 25 | $163.7M | $1.4B | ||
| Q1 25 | $167.1M | $1.4B | ||
| Q4 24 | $161.0M | $1.4B | ||
| Q3 24 | $162.6M | $1.3B | ||
| Q2 24 | $156.4M | $1.3B |
| Q1 26 | — | $3.4B | ||
| Q4 25 | $261.1M | $3.3B | ||
| Q3 25 | $264.8M | $3.3B | ||
| Q2 25 | $254.9M | $3.3B | ||
| Q1 25 | $252.7M | $3.3B | ||
| Q4 24 | $240.9M | $3.3B | ||
| Q3 24 | $245.3M | $3.2B | ||
| Q2 24 | $235.8M | $3.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.9M | $39.1M |
| Free Cash FlowOCF − Capex | $7.6M | — |
| FCF MarginFCF / Revenue | 6.1% | — |
| Capex IntensityCapex / Revenue | 1.9% | 1.5% |
| Cash ConversionOCF / Net Profit | 2.41× | 1.73× |
| TTM Free Cash FlowTrailing 4 quarters | $28.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $39.1M | ||
| Q4 25 | $9.9M | $182.7M | ||
| Q3 25 | $18.5M | $55.7M | ||
| Q2 25 | $4.3M | $43.5M | ||
| Q1 25 | $2.6M | $32.6M | ||
| Q4 24 | $12.2M | $153.2M | ||
| Q3 24 | $9.6M | $36.6M | ||
| Q2 24 | $1.3M | $41.2M |
| Q1 26 | — | — | ||
| Q4 25 | $7.6M | $81.8M | ||
| Q3 25 | $16.8M | $26.1M | ||
| Q2 25 | $3.0M | $19.6M | ||
| Q1 25 | $1.5M | $11.9M | ||
| Q4 24 | $10.0M | $42.5M | ||
| Q3 24 | $7.9M | $12.2M | ||
| Q2 24 | $-2.0M | $19.9M |
| Q1 26 | — | — | ||
| Q4 25 | 6.1% | 68.4% | ||
| Q3 25 | 13.1% | 21.7% | ||
| Q2 25 | 2.6% | 17.2% | ||
| Q1 25 | 1.3% | 10.0% | ||
| Q4 24 | 8.5% | 36.6% | ||
| Q3 24 | 6.9% | 10.8% | ||
| Q2 24 | -1.9% | 18.6% |
| Q1 26 | — | 1.5% | ||
| Q4 25 | 1.9% | 84.4% | ||
| Q3 25 | 1.3% | 24.6% | ||
| Q2 25 | 1.2% | 20.9% | ||
| Q1 25 | 1.0% | 17.5% | ||
| Q4 24 | 1.9% | 95.1% | ||
| Q3 24 | 1.5% | 21.7% | ||
| Q2 24 | 3.0% | 20.1% |
| Q1 26 | — | 1.73× | ||
| Q4 25 | 2.41× | 14.71× | ||
| Q3 25 | 3.46× | 3.73× | ||
| Q2 25 | 0.81× | 0.75× | ||
| Q1 25 | 0.55× | 3.97× | ||
| Q4 24 | — | 5.09× | ||
| Q3 24 | 2.21× | 4.03× | ||
| Q2 24 | 0.97× | 1.34× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
UE
| Rental revenue | $124.2M | 94% |
| Other | $8.4M | 6% |
